New hope for recurrent throat cancer: Radiation-Immunotherapy combo shows promise

This phase II trial tests a new approach for recurrent nasopharyngeal carcinoma (a type of throat cancer) that has come back after initial treatment and cannot be removed by surgery. The treatment combines a special radiation schedule (low and high doses) with an immunotherapy drug (anti-PD-1) to boost the immune system's attack on cancer cells. The study will enroll 23 participants and measure how well the cancer responds after 3 months, as well as long-term survival and side effects.